Pharmaceutical Business review

Proteonomix’s subsidiary signs LOI with Sinoquest

The products include Proteoderm’s special high end formulation and an over-the-counter formulation, currently under development. Proteoderm intends to sell to Sinoquest the pre-mixed material in bulk and a license of its name and the right to use the material in Sinoquest’s own containers. Both companies expect to begin distribution in the first quarter of 2009.

Michael Cohen, president of Proteonomix, said: “After years of R&D, Proteoderm’s products are now ready for commercialization. Proteoderm is pleased to enter this letter of intent (LOI) with Sinoquest because of Sinoquest’s ownership interests in several distribution networks including channels for pharmaceutical and cosmetic products in China.”